Prof. Ján Mojžiš, DVM, D.Sc.

Last update: 23. 10. 2023

I. BASIC INFORMATION
I.1 Surname Mojžiš
I.2 Name Ján
I.3 Titles Prof. , DVM, D.Sc.
I.4 Year of birth 1955
I.5 Name of the workplace University of Veterinary Medicine and Pharmacy in Košice, Pavol Jozef Šafárik University in Košice
I.6 Address of the workplace Komenského 73, 041 81 Košice, Slovak Republic
I.7 Position professor
I.8 E-mail address jan.mojzis@upjs.sk
I.9 Hyperlink to the entry of a person in the Register of university staff https://www.portalvs.sk/regzam/detail/14977
I.10 Name of the study field in which a person works at the university pharmacy
I.11 ORCID iD 3 https://orcid.org/0000-0002-7974-4525
3 Optional item.

II. HIGHER EDUCATION AND FURTHER QUALIFICATION GROWTH
II.a Name of the university or institution II.b Year II.c Study field and programme
II.1 First degree of higher education
II.2 Second degree of higher education Veterinary College in Košice 1980 general veterinary medicine
II.3 Third degree of higher education Veterinary College in Košice 1991 biochemistry
II.4 Associate professor Pavol Jozef Šafárik University in Košice, Faculty of Medicine 1996 pharmacology
II.5 Professor Pavol Jozef Šafárik University in Košice, Faculty of Medicine 2003 pharmacology
II.6 Doctor of Science (DrSc.) Pavol Jozef Šafárik University, Faculty of Medicine 2012 pharmacology

III. CURRENT AND PREVIOUS EMPLOYMENT
III.a Occupation-position III.b Institution III.c Duration
Professor avol Jozef Šafárik University, Faculty of Medicine, Institute of Pharmacology 2003 up to now
Assotiate professor Pavol Jozef Šafárik University, Faculty of Medicine, Institute of Pharmacology 1996 2003
Researcher Pavol Jozef Šafárik University, Faculty of Medicine, Institute of Pharmacology 1988 1996
Researcher Military veterinary training and research institute, Košice 1980 1988

IV. DEVELOPMENT OF PEDAGOGICAL, PROFESSIONAL, LANGUAGE, DIGITAL AND OTHER SKILLS
IV.a Activity description, course name, other IV.b Name of the institution IV.c Year
Military veterinary training and research institute, Košice 1984
Veterinary College in Košice 1980

V. OVERVIEW OF ACTIVITIES WITHIN THE TEACHING CAREER AT THE UNIVERSITY
V.1. Overview of the profile courses taught in the current academic year according to study programmes
V.1.a Name of the profile course V.1.b Study programme V.1.c Degree V.1.d Field of study

V.2. Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year 4
V.2.a Study programme V.2.b Degree V.2.d Field of study
4 According to Art. 6 para. 4 of the Standards for the Study Programme.

V.3. Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.3.a Name of the field of habilitation procedure and inaugural procedure V.3.b Study field to which it is assigned

V.4. Overview of supervised final theses
V.4.a Bachelor's (first degree) V.4.b Diploma (second degree) V.4.c Dissertation (third degree)
V.4.1 Number of currently supervised theses 0 0 3
V.4.2 Number of defended theses 0 4 15

V.5. Overview of other courses taught in the current academic year according to study programmes
V.5.a Name of the course V.5.b Study programme V.5.c Degree V.5.d Field of study
Free radicals and antioxidantspharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy
Phytopharmaceuticalspharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy

VI. OVERVIEW OF THE RESEARCH/ARTISTIC/OTHER OUTPUTS
VI.1. Overview of the research/artistic/other outputs and the corresponding citations
VI.1.a Overall VI.1.b Over the last six years
VI.1.1 Number of the research/artictic/other outputs 610 118
VI.1.2 Number of the research/artictic/other outputs registered in the Web of Science or Scopus databases 195 55
VI.1.3 Number of citations corresponding to the research/artictic/other outputs 2329 1195
VI.1.4 Number of citations registered in the Web of Science or Scopus databases 1988 1134
VI.1.5 Number of invited lectures at the international, national level 1 1

VI.2. The most significant research/artistic/other outputs 5
1. ADC: Mojzis J., Varinska L., Mojzisova G., Kostova I, Mirossay L.: antiangogenic effect of flavonoids and chalcones. Pharmacol. Res. 57, 259-265, 2008 (IF=3,929; Q1) cit. 207x
2. ADC: Lukáč M, Mojžiš J, Mojžišová G, Mrva M, Ondriska F, Valentová J, Lacko I, Bukovský M, Devínsky F, Karlovská J.: Dialkylamino and nitrogen heterocyclic analogues of hexadecylphosphocholine and cetyltrimetylammonium bromide: Effect of phosphate group and environment of the ammonium cation on their biological activity. Eur J Med Chem. 44, 4970-4977, 2009. (IF=3,269; Q2) cit. 22x
3. ADC: Pilatova M, Varinska L, Perjesi P, Sarissky M, Mirossay L, Solar P, Ostro A, Mojzis J.: In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicol In Vitro. 24, 1347-1355, 2010. (IF=2,959; Q1) cit. 41x
4. ADC: Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A.: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 10, 62-69, 2010. (IF=4,306; Q1) cit. 73x
5. ADC: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit. 38x.
5 Maximum of five most significant outputs, if the RATP form is attached to the application.

VI.3. The most significant research/artistic/other outputs over the last six years 6
1. ADC: Mirossay L, Varinská L, Mojžiš J. Antiangiogenic Effect of Flavonoids and Chalcones: An Update. Int J Mol Sci. 19, pii: E27., 2018 (IF=3,226; Q1) cit. 48 x
2. ADC: Kubatka P, Kello M, Kajo K, Kruzliak P, Výbohová D, Mojžiš J, Adamkov M, Fialová S, Veizerová L, Zulli A, Péč M, Statelová D, Grančai D, Büsselberg D. Oregano demonstrates distinct tumour-suppressive effects in the breast carcinoma model. Eur J Nutr. 56, 1303-1316, 2017 (IF=3,467; Q1). cit. 21x
3. ADC: Kapinova, A., Stefanicka, P., Kubatka, P., Zubor, P., Uramova, S., Kello, M., Mojzis, J., Blahutova, D., Qaradakhi, T., Zulli, A., Caprnda, M., Danko, J., Lasabova, Z., Busselberg, D., Kruzliak, P.: Are plant-based functional foods better choice against cancer than single phytochemicals? A critical review of current breast cancer research. Biomed Pharmacother. 96, 1465–1477, 2017 (IF= 2,326; Q1) cit. 51 x
4. ADM: Kello M, Takac P, Kubatka P, Kuruc T, Petrova K, Mojzis J. Oxidative Stress-Induced DNA Damage and Apoptosis in Clove Buds-Treated MCF-7 Cells. Biomolecules 10, pii: E139, 2020 (IF=4,649; Q1) cit. 8 x
5. ADM: Takac P, Kello M, Vilkova M, Vaskova J, Michalkova R, Mojzisova G, Mojzis J. Antiproliferative Effect of Acridine Chalcone Is Mediated by Induction of Oxidative Stress. Biomolecules 10, pii: E345, 2020 (IF=4,649; Q1) cit. 12 x
6 Maximum of five most significant outputs over the last six years, if the RATP form is attached to the application.

VI.4. The most significant citations corresponding to the research/artistic/other outputs 7
1. Citovaný dokument: Mojzis J., Varinska L., Mojzisova G., Kostova I, Mirossay L.: Antiangogenic effect of flavonoids and chalcones. Pharmacol. Res. 57, 259-265, 2008 (IF=3,929; Q1 - SJR) cit. 207x Oh
2. Citovaný dokument: ADC: Solárová Z., Mojžiš J., Solár P.: Hsp90 inhibitor as a sensitizer of cancer cells to different therapies. Int J Oncol 46: 907-926, 2015 (IF=2,773; Q2); cit. 52x Ohlas: ADC: Pawar, Mercy; Busov, Boris; Chandrasekhar, Aaruran; et al. FAS apoptotic inhibitory molecule 2 is a stress-induced intrinsic neuroprotective factor in the retina Cell Death Differ 24, 1799-1810, 2017 (IF=8,291; Q1)
3. Citovaný dokument: Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A.: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 10, 62-69, 2010. (IF=4,306; Q1) cit. 73x Ohlas: ADC: Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., Taguchi K., Sasaki Y., Takashima, S.: A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23, 1441-1448, 2012. (IF=7,384; Q1)
4. Citovaný dokument: Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J.: Soy and Breast Cancer: Focus on Angiogenesis. Int J Mol Sci. 16, 11728-11749, 2015 (IF= 3.257; Q1). cit. 102x; Ohlas: ADC: Molina, Luis; Bustamante, Felipe A.; Bhoola, Kanti D.; et al. Possible role of phytoestrogens in breast cancer via GPER-1/GPR30 signaling. Clin Sci 132, 2583-2598, 2018 (IF=5,22; Q1)
5. Citovaný dokument: Mirossay L, Varinská L, Mojžiš J. Antiangiogenic Effect of Flavonoids and Chalcones: An Update. Int J Mol Sci. 19, pii: E27., 2018 (IF=3,226; Q1) cit. 48x; Ohlas: ADC: Zheng, Dan; Zhao, Jingyang; Tao, Yinghua; Liu, J; Wang, LY; He, J; Lei, JD; Liu, KF. pH and glutathione dual responsive nanoparticles based on Ganoderma lucidum polysaccharide for potential programmable release of three drugs. Chem Engin J 389, Article No. 124418, 2020 (IF=13, 273; Q1)
7 Maximum of five most significant citations, if the RATP form is attached to the application.

VI.5. Participation in conducting (leading) the most important research projects or art projects over the last six years 8
1. APVV–0408–12: Galektíny a angiogenéza. 2013-2017: Zodpovedný riešiteľ: prof. MVDr. Ján Mojžiš, DrSc.
2. APVV-16-0446; Bunkové interakcie v nádorovom mikroprostredí a ich farmakologické ovplyvnenie. 2017-2021: Zodpovedný riešiteľ od roku 2018 - prof. MVDr. Ján Mojžiš, DrSc.
3. VEGA 1/0753/17; Vplyv prírodných látok na nádorové mikroprostredie. 2017-2020. Zodpovedný riešiteľ: prof. MVDr. J. Mojžiš, DrSc.
4. VEGA 1/0539/21; Fibroblasty a nádorové mikroprostredie: bunkové interakcie a ich farmakologické ovplyvnenie. 2021-2024. Zodpovedný riešiteľ: prof. MVDr. J. Mojžiš, DrSc.
5. Štrukturálne fondy: OPENMED Kód ITMS2014+:313011V455. Zodpovedný riešiteľ aktivity 7.1: prof. MVDr. J. Mojžiš, DrSc.
8 Maximum of five most significant projects, if the RATP form is attached to the application. In addition to the name and brief characteristics of the project, the type of participation is indicated (in Slovak and in English), if possible, a hyperlink to the project and its outputs and citations are stated as well.

VII. OVERVIEW OF ORGANIZATIONAL EXPERIENCE RELATED TO HIGHER EDUCATION AND RESEARCH/ARTISTIC/OTHER ACTIVITIES 9
VII.a Activity, position VII.b Name of the institution, board VII.c Duration
Vice-chairman of the PJŠU Attestation Commission in Košice Pavol Jozef Šafárik University in Košice 2015 up to now
Member of the APVV commission for medical sciences Ministry of Education, Science, Research and Sports of the Slovak Republic 2015 up to now
Member of the commission no. 9. VEGA Ministry of Education, Science, Research and Sports of the Slovak Republic 2013 2020
Member of Scietifical Board Pavol Jozef Šafárik University in Košice 2011 2015
Member of the committee of the Slovak Pharmacological Society SLS 2010 up to now
Member of the committee for the defense of dissertations in the field of Pharmacology; Member of the committee for the defense of dissertations in the field of Molecular Cytology Pavol Jozef Šafárik University in Košice 2004 up to now
9 E.g. academic positions, memberships in editorial boards and in scientific and professional societies.

VIII. OVERVIEW OF INTERNATIONAL MOBILITIES AND VISITS ORIENTED ON EDUCATION AND RESEARCH/ARTISTIC/ OTHER ACTIVITIES IN THE GIVEN FIELD OF STUDY
VIII.a Name of the institution VIII.b Address of the institution VIII.c Duration (indicate the duration of stay) VIII.d Mobility scheme, employment contract, other (describe)

IX. OTHER RELEVANT FACTS 10
IX.a If relevant, other activities related to higher education or research/artictic/other activities are mentioned
1. in 1996 and 1998 - first author and co-author of papers that were evaluated as the best publications at the Faculty of Medicine UPJŠ 2. 1997 - co-author of a textbook of pharmacology, evaluated as the best monograph at the Faculty of Medicine UPJŠ 3. 2000 - award of a professional society for a set of papers 4. 2001 - author of the best monograph at LF UPJŠ 5. 2002 - co-author of a publication that placed 2nd at LF UPJŠ 6. 2005 - co-author of a publication that placed 2nd at LF UPJŠ 7. 2013 – Vladimír Novotný Award for the best original work for the year 2012 in the journal Psychiatry for practice (co-author) 8. 2015 – Rector's Award of UPJŠ in Košice for scientific research and publication activity 9. Co-guarantor of EU structural funds projects (coordinator Prof. MUDr. L. Mirosay, DrSc.): Network of excellence workplaces for oncology (SEPO) Building infrastructure in the center of excellence SEPO-II 10. Member of the editorial board of Folia Medica Cassoviensia, Transactions of the Universities of Košice, International Journal of Current Chemistry 11. Chairman of the organizing committee of the 62nd Farmakologický dni, Košice, 2012 12. Reviewer of about 100 articles sent to scientific journals. 13. Hirsch index 28
10 Maximum of 1800 characters, if the RATP form is attached to the application.
Skip to content